HUM:NYE-Humana Inc. (USD)

EQUITY | Healthcare Plans | New York Stock Exchange

Last Closing

USD 358.93

Change

0.00 (0.00)%

Market Cap

USD 30.56B

Volume

0.87M

Analyst Target

USD 448.08
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Humana Inc is a health care company that offers insurance products and health and wellness services. Its segments include Retail, Employer Group and Healthcare Services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Healthcare Plans

Symbol Name Price(Change) Market Cap
UNH UnitedHealth Group Incorporate..

N/A

USD 457.54B
ELV Elevance Health Inc

N/A

USD 122.56B
CI Cigna Corp

N/A

USD 95.46B
CVS CVS Health Corp

N/A

USD 75.60B
CNC Centene Corp

N/A

USD 36.78B
MOH Molina Healthcare Inc

N/A

USD 17.99B
OSCR Oscar Health Inc

N/A

USD 4.56B
NEUE NeueHealth Inc

N/A

USD 0.05B

ETFs Containing HUM

IHF iShares U.S. Healthcare P.. 4.68 % 0.43 %

N/A

USD 0.76B
TUSB:CA TD Select U.S. Short Term.. 2.16 % 0.28 %

N/A

CAD 7.68M
TUSB-U:CA TD Select U.S. Short Term.. 2.16 % 0.00 %

N/A

CAD 8.25M
FUM:CA 0.00 % 0.80 %

N/A

N/A
DUSA 0.00 % 0.63 %

N/A

N/A
VETS 0.00 % 0.60 %

N/A

N/A
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
LONG:CA CI Global Longevity Econo.. 0.00 % 0.00 %

N/A

CAD 3.80M
GBLO 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Healthcare Plans) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.60% 25% F 9% A-
Dividend Return 0.19% 20% F 7% C-
Total Return -21.41% 25% F 8% B-
Trailing 12 Months  
Capital Gain -19.46% 13% F 12% F
Dividend Return 0.79% 20% F 9% A-
Total Return -18.66% 13% F 11% F
Trailing 5 Years  
Capital Gain 40.88% 50% F 68% D+
Dividend Return 5.70% 25% F 18% F
Total Return 46.59% 50% F 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.96% 50% F 68% D+
Dividend Return 9.67% 50% F 64% D
Total Return 0.71% 40% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 20.75% 63% D 51% F
Risk Adjusted Return 46.60% 63% D 69% C-
Market Capitalization 30.56B 56% F 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Healthcare Plans) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.50 43% 36%
Price/Book Ratio 2.32 63% 37%
Price / Cash Flow Ratio 10.65 44% 36%
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity 12.10% 67% 65%
Return on Invested Capital 11.55% 78% 70%
Return on Assets 4.91% 67% 72%
Debt to Equity Ratio 62.80% 44% 53%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector